Molecular targets of current and prospective heart failure therapies
- Correspondence to Dr Larissa Lipskaia, Cardiovascular Research Center, Mount Sinai School of Medicine, New York, NY 10029, USA;
- Received 4 November 2012
- Revised 4 November 2012
- Accepted 27 December 2012
- Published Online First 24 January 2013
Heart failure (HF) is a vicious circle in which an original insult leading to mechanical cardiac dysfunction initiates multiple morphological, biochemical and molecular pathological alterations referred to as cardiac remodelling. Remodelling leads to further deterioration of cardiac function and functional reserve. Interrupting or reversing cardiac remodelling is a major therapeutic goal of HF therapies. The role of molecules and molecular pathways in cardiac remodelling and HF has been extensively studied. Multiple approaches are now used or investigated in HF therapy, including pharmacological therapy, device therapy, gene therapy, cell therapy and biological therapy targeting cytokines and growth factors. This review explores the molecular targets and molecular bases of current and prospective therapies in HF.